A Countrywide Seroepidemiological Survey of Rift Valley Fever in Livestock, Uganda, 2017.


Journal

The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507

Informations de publication

Date de publication:
06 09 2023
Historique:
received: 08 08 2022
accepted: 01 05 2023
medline: 8 9 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: epublish

Résumé

In 2016, an outbreak of Rift Valley fever was reported in the Kabale District in Uganda for the first time in 48 years. Three human cases were confirmed by polymerase chain reaction, and subsequent serological investigations revealed an overall IgG seropositivity of 13% in humans and 13% in animals. In response to this reemergence, we designed a countrywide survey to determine the seropositivity of anti-Rift Valley fever virus (RVFV) IgG antibodies in livestock. Samples were collected from 27 districts and tested for RVFV anti-IgG antibodies. A total of 3,181 livestock samples were tested, of which 54.4% were cattle (1,732 of 3,181), 34.3% were goats (1,091 of 3,181), and 11.3% were sheep (358 of 3,181). Overall RVFV seropositivity was 6.9% (221 of 3,181). Seroprevalence was greater in cattle (10.7%) compared with goats (2.6%) and sheep (2.0%), among females (7.5%) compared with males (5.2%), and among adults (7.6%) compared with juveniles (4.9%) and nurslings (6.4%). Exotic breeds and animals with a history of abortion or stillbirth also had greater odds of RVFV seropositivity. Animals grazed under tethering and paddocking had greater RVFV seropositivity compared with animals that grazed communally, and livestock in the western and eastern regions had the greatest seroprevalence. In a multivariate regression model, animal species (odds ratio [OR], 6.4; 95% CI, 3.5-11.4) and age (OR, 2.3; 95% CI, 1.4-3.6) were associated significantly with RVFV seropositivity. This study could be important in developing risk-based surveillance for early outbreak detection to limit the spread of RVFV in both human and animal populations.

Identifiants

pubmed: 37524326
doi: 10.4269/ajtmh.22-0504
pii: tpmd220504
pmc: PMC10484263
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

548-553

Références

Emerg Infect Dis. 2002 Dec;8(12):1415-20
pubmed: 12498657
PLoS Negl Trop Dis. 2018 May 3;12(5):e0006412
pubmed: 29723189
PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006353
pubmed: 29698487
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):43-51
pubmed: 20682905
Am J Trop Med Hyg. 2019 Mar;100(3):659-671
pubmed: 30675833
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):58-64
pubmed: 20682907
J S Afr Vet Assoc. 2017 Jan 20;88(0):e1-e5
pubmed: 28240033
Onderstepoort J Vet Res. 2021 Feb 03;88(1):e1-e5
pubmed: 33567844
Expert Opin Biol Ther. 2019 Dec;19(12):1333-1342
pubmed: 31478397
Am J Trop Med Hyg. 2023 Mar 06;108(4):712-721
pubmed: 36878208
J Immunol Res. 2016;2016:7346294
pubmed: 27689098
Curr Opin Virol. 2018 Apr;29:8-15
pubmed: 29514112
Prev Vet Med. 2006 Aug 17;75(3-4):251-66
pubmed: 16797092
J Infect Dis. 1984 Mar;149(3):311-9
pubmed: 6371153
Expert Rev Vaccines. 2017 Jun;16(6):601-611
pubmed: 28425834
Clin Infect Dis. 2003 Oct 15;37(8):1084-92
pubmed: 14523773
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):28-37
pubmed: 20682903
BMC Vet Res. 2018 Sep 3;14(1):271
pubmed: 30176865
BMC Vet Res. 2021 Apr 13;17(1):157
pubmed: 33849526

Auteurs

Luke Nyakarahuka (L)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.
Department of Biosecurity, Ecosystems and Veterinary Public Health, Makerere University, Kampala, Uganda.

Jackson Kyondo (J)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.

Carson Telford (C)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Amy Whitesell (A)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Alex Tumusiime (A)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.

Sophia Mulei (S)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.

Jimmy Baluku (J)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.

Caitlin M Cossaboom (CM)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Deborah L Cannon (DL)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Joel M Montgomery (JM)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Julius J Lutwama (JJ)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.

Stuart T Nichol (ST)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Stephen Balinandi (S)

Department of Arbovirology, Emerging and Reemerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.

John D Klena (JD)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Trevor R Shoemaker (TR)

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH